- Home
- EQS vs ICU Comparison
EQS vs ICU Comparison
Compare EQS & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- ICU
- Stock Information
- Founded
- EQS 1991
- ICU 2018
- Country
- EQS United States
- ICU United States
- Employees
- EQS N/A
- ICU N/A
- Industry
- EQS Finance Companies
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- EQS Finance
- ICU Health Care
- Exchange
- EQS Nasdaq
- ICU Nasdaq
- Market Cap
- EQS 30.7M
- ICU 25.6M
- IPO Year
- EQS N/A
- ICU N/A
- Fundamental
- Price
- EQS $2.44
- ICU $0.87
- Analyst Decision
- EQS
- ICU
- Analyst Count
- EQS 0
- ICU 0
- Target Price
- EQS N/A
- ICU N/A
- AVG Volume (30 Days)
- EQS 77.7K
- ICU 1.1M
- Earning Date
- EQS 01-01-0001
- ICU 11-12-2025
- Dividend Yield
- EQS N/A
- ICU N/A
- EPS Growth
- EQS N/A
- ICU N/A
- EPS
- EQS N/A
- ICU N/A
- Revenue
- EQS $1,355,000.00
- ICU $766,000.00
- Revenue This Year
- EQS N/A
- ICU $894.81
- Revenue Next Year
- EQS N/A
- ICU $71.78
- P/E Ratio
- EQS N/A
- ICU N/A
- Revenue Growth
- EQS 60.35
- ICU N/A
- 52 Week Low
- EQS $0.74
- ICU $0.31
- 52 Week High
- EQS $2.48
- ICU $5.34
- Technical
- Relative Strength Index (RSI)
- EQS 77.42
- ICU 54.67
- Support Level
- EQS $2.31
- ICU $0.83
- Resistance Level
- EQS $2.48
- ICU $0.91
- Average True Range (ATR)
- EQS 0.12
- ICU 0.07
- MACD
- EQS 0.02
- ICU -0.00
- Stochastic Oscillator
- EQS 92.16
- ICU 54.45
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.